Our current therapeutic focus is the continued development of the novel drug, lotilaner.
By applying our unique approach to research and development, we’re investigating solutions to target meibomian gland disease (MGD), rosacea, Lyme disease prevention, and community reduction of malaria.
We’re looking for new ways to apply proven science to solve large problems. Our pipeline of wholly owned candidates addresses a number of diseases with high unmet needs across a range of therapeutic categories including eye care, dermatology, and infectious disease prevention.
Many parasite-mediated diseases have high clinical unmet needs. By applying our unique approach to research and development, we’re investigating solutions to target MGD, rosacea, Lyme disease prevention, and community reduction of malaria.
MGD is a broad term used to describe a dysfunction of the meibomian glands that may result in alteration of the tear film, symptoms of eye irritation, clinically apparent inflammation, and ocular surface disease. We are evaluating XDEMVY in a Phase 2a trial for MGD.
PPR is a chronic skin disease characterized by facial redness, inflammatory lesions, and burning and stinging, which can flare up in response to certain triggers such as sun exposure or emotional stress. According to the US National Rosacea Society, approximately 16 million people in the United States are affected by rosacea. PPR is estimated to occur in 18% to 28% of patient with rosacea. We are developing TP-04 as a topical formulation.
Lyme disease is the most common vector-borne disease in the United States, caused by an infection of Borrelia bacteria following a bite by a tick. Estimates of annual cases of Lyme disease in the United States range from approximately 300,000 to 400,000. We are developing TP-05 as an oral formulation that is designed as a prophylactic drug against Lyme disease to eradicate the tick before it can transmit the Borrelia bacteria. TP-05 also has the potential to cause the death of mosquitos that transmit malaria. Malaria is one of the world’s highest unmet public health needs, with approximately 247 million cases and more than 600,000 deaths worldwide.
*XDEMVY is FDA approved only for the treatment of Demodex blepharitis. XDEMVY is currently being investigated in a Phase 2a trial for MGD.
Please reach out to us using the form below.
"*" indicates required fields